Abstract
The elucidation of the triggering molecular mechanism of chronic myeloid leukemia gave rise to the development of imatinib, a tyrosine kinase inhibitor and a prototype of target-oriented drugs. Imatinib led to impressing response and survival rates and now represents the standard therapy of CML. However, a significant proportion of patients do not tolerate or fail to respond to imatinib treatment. Alternative therapies can be offered to those patients. The particular challenge of CML patient management is to recognize an impending imatinib failure by adequate surveillance and to know about therapeutic options to prevent progression of the disease to accelerated phase or blast crisis since these are more difficult to control. Targeted therapy with second-generation tyrosine kinase inhibitors should be used in synopsis with mutational analysis and the patients history. In this review we present current knowledge of diagnosis, monitoring and therapy strategies of patients with CML.
Keywords: Chronic myeloid leukemia, imatinib, dasatinib, nilotinib, BCR-ABL, mutation, rare disease, diagnosis, lymphoblastic, fatigue, weight loss, abdominal discomfort, splenomegaly, myeloproliferative neoplasm (MPN), polycythemia vera, thrombocythemia, Leukemia Virus, hematopoietic cells, blood counts, complete hematologic remission (CHR), malignant cells, histologic, cytologic, White blood cell count, fluorescence, hybridization (FISH), metaphases, Plasma Leve, intestinal absorption, metabolism, glycoprotein, hydroxyurea, arsenic, splenectomy, splenic irradiation, busulfan, pregnancy, ribonucleotide, tyrosine kinase inhibitors (TKI), antimetabolite cytarabine, monotherapy, autophosphorylation, bioavailability, phosphate-binding, nucleotide polymorphisms, DOSE, potency, pharmacokinetics, first line therapy, lymphoid, blood-brain barrier, toxicity, Stem Cell Transplantation (SCT), autologous SCT, chemotherapy, diabetes, electrocardiograms
Current Cancer Drug Targets
Title: Current Treatment Concepts of CML
Volume: 11 Issue: 1
Author(s): A. A. Leitner, A. Hochhaus and M. C. Muller
Affiliation:
Keywords: Chronic myeloid leukemia, imatinib, dasatinib, nilotinib, BCR-ABL, mutation, rare disease, diagnosis, lymphoblastic, fatigue, weight loss, abdominal discomfort, splenomegaly, myeloproliferative neoplasm (MPN), polycythemia vera, thrombocythemia, Leukemia Virus, hematopoietic cells, blood counts, complete hematologic remission (CHR), malignant cells, histologic, cytologic, White blood cell count, fluorescence, hybridization (FISH), metaphases, Plasma Leve, intestinal absorption, metabolism, glycoprotein, hydroxyurea, arsenic, splenectomy, splenic irradiation, busulfan, pregnancy, ribonucleotide, tyrosine kinase inhibitors (TKI), antimetabolite cytarabine, monotherapy, autophosphorylation, bioavailability, phosphate-binding, nucleotide polymorphisms, DOSE, potency, pharmacokinetics, first line therapy, lymphoid, blood-brain barrier, toxicity, Stem Cell Transplantation (SCT), autologous SCT, chemotherapy, diabetes, electrocardiograms
Abstract: The elucidation of the triggering molecular mechanism of chronic myeloid leukemia gave rise to the development of imatinib, a tyrosine kinase inhibitor and a prototype of target-oriented drugs. Imatinib led to impressing response and survival rates and now represents the standard therapy of CML. However, a significant proportion of patients do not tolerate or fail to respond to imatinib treatment. Alternative therapies can be offered to those patients. The particular challenge of CML patient management is to recognize an impending imatinib failure by adequate surveillance and to know about therapeutic options to prevent progression of the disease to accelerated phase or blast crisis since these are more difficult to control. Targeted therapy with second-generation tyrosine kinase inhibitors should be used in synopsis with mutational analysis and the patients history. In this review we present current knowledge of diagnosis, monitoring and therapy strategies of patients with CML.
Export Options
About this article
Cite this article as:
A. Leitner A., Hochhaus A. and C. Muller M., Current Treatment Concepts of CML, Current Cancer Drug Targets 2011; 11 (1) . https://dx.doi.org/10.2174/156800911793743637
DOI https://dx.doi.org/10.2174/156800911793743637 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Intracellular Trafficking of Plasmids for Gene Therapy: Mechanisms of Cytoplasmic Movement and Nuclear Import
Current Gene Therapy Use of Cell Lines in the Investigation of Pharmacogenetic Loci
Current Pharmaceutical Design Antifolate Inhibitors of Thymidylate Synthase as Anticancer Drugs
Mini-Reviews in Medicinal Chemistry Viral Vectors for Gene-Directed Enzyme Prodrug Therapy
Current Gene Therapy Discovery of Structural Prospects of Imidazo[1,5-a]pyrazine Derivatives as BTK Inhibitors Against Cancer: A Computational Study
Letters in Drug Design & Discovery In or Out Stemness: Comparing Growth Factor Signalling in Mouse Embryonic Stem Cells and Primordial Germ Cells
Current Stem Cell Research & Therapy The Transcription Factor ETS-1: Its Role in Tumour Development and Strategies for its Inhibition
Mini-Reviews in Medicinal Chemistry Safety Profile of Plasmid/Liposomes and Virus Vectors in Clinical Gene Therapy
Current Drug Safety Chronic Diseases and COVID-19: A Review
Endocrine, Metabolic & Immune Disorders - Drug Targets Targeted Drugs and Nanomedicine: Present and Future
Current Pharmaceutical Design Disseminated Intravascular Coagulation in Leukemia and Sepsis
Vascular Disease Prevention (Discontinued) Phytochemicals and Cancer Stem Cells: A Pancreatic Cancer Overview
Current Chemical Biology In Vitro Antitumoral Activity of Palladium(II) and Platinum(II) Complexes with O,O'-Dialkyl Esters of Ethylene-bis(S)-Leucine
Letters in Drug Design & Discovery Lipid-Based Nanoparticulate Systems for the Delivery of Anti-Cancer Drug Cocktails: Implications on Pharmacokinetics and Drug Toxicities
Current Drug Metabolism Targeting JAK/STAT Signaling Pathway in Inflammatory Diseases
Current Signal Transduction Therapy Delineation of Current Development of Antimitotic Compounds Targeting Cytoskeletal Protein Tubulin and Microtubule in the Cancer Therapy
Current Chemical Biology Pharmacogenetics of Phase I and Phase II Drug Metabolism
Current Pharmaceutical Design Small Molecule Aurora Kinases Inhibitors
Current Medicinal Chemistry Hypoxia: Targeting the Tumour
Anti-Cancer Agents in Medicinal Chemistry Nanotherapeutics in Tumour Microenvironment for Cancer Therapy
Nanoscience & Nanotechnology-Asia